Latest Oneview Healthcare (ASX:ONE) News

Oneview Healthcare boosted its cash reserves to €10.3 million by completing a significant capital raise and is progressing its AI-powered Care Assistant, Ovie, with pilot deployments planned for 2026.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Oneview Healthcare has secured A$12.3 million from its placement and security purchase plan, though the SPP fell well short of its A$2 million target. The company will now seek shareholder approval for the final tranche of its A$19 million raise at the September AGM.

Oneview Healthcare PLC has launched a Security Purchase Plan (SPP) to raise up to A$2 million, following a recent A$19 million placement. The SPP offers eligible shareholders discounted shares to support AI development and customer deployments.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

Oneview Healthcare has successfully raised A$19 million through a two-tranche placement and launched a Security Purchase Plan to further strengthen its financial position and accelerate AI development.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

Oneview Healthcare reported a stronger cash position in Q4 2025 alongside a key expansion of its US footprint through a new partnership with a Top 10 health system. The company’s strategic moves set the stage for growth in 2026.

Oneview Healthcare reported robust commercial growth in 2025, driven by new US client wins and the launch of its AI-powered care assistant, Ovie. The company enters 2026 with a confident outlook focused on expanding its US footprint and advancing digital health innovation.

Oneview Healthcare reported a €2.2 million net cash outflow in Q3 2025, impacted by delayed customer payments, while expanding its U.S. footprint with a new client and advancing deployments.